Screening for a Potent Antibacterial Peptide to Treat Mupirocin-Resistant MRSA Skin Infections

Activity of aurisin A isolated from Neonothopanus nambi against methicillin-resistant Staphylococcus aureus strains

“…Vancomycin, which also showed a time-dependent bactericidal activity, was reported to exhibit a slow killing rate against MRSA ( Isnansetyo & Kamei, 2003 ). Antibacterial compounds with rapid bactericidal activity are considered potential as they can rapidly eliminate the pathogen and thereby reduce the chances for resistance development ( Ng et al, 2017 ). The distinction of superiority between bactericidal and bacteriostatic agents from in vitro studies, however, is of little relevance when treating infection in clinical situations.…”

Designing a leucine‐rich antibacterial nonapeptide with potent activity against mupirocin‐resistant MRSA via a structure–activity relationship study

“…As a starting point, we conducted a head‐to‐head minimum inhibitory concentration (MIC) comparison of 61 AMPs, up to 11 residues long, against mupirocin‐resistant MRSA (Ng, Ching, et al., 2017). The most potent AMP was found to be the 11‐residue peptide 3.1 (KKLLKWLLKLL‐NH2), designed by Kang and co‐workers at Seoul National University (Kang et al., 2009) which exhibited an MIC of 3.13 µM against mupirocin‐resistant MRSA (Ng, Ching, et al., 2017). Peptide 3.1 is a leucine‐ and lysine‐rich synthetic peptide rationally designed from alpha‐helical wheel modelling (Kang et al., 2009).…”

“…For the second hurdle, manufacturing cost can be kept low by minimizing peptide length and designing AMPs made up of cheaper amino acids and avoiding expensive amino acids like arginine, tryptophan and unnatural amino acids. As a starting point, we conducted a head‐to‐head minimum inhibitory concentration (MIC) comparison of 61 AMPs, up to 11 residues long, against mupirocin‐resistant MRSA (Ng, Ching, et al., 2017). The most potent AMP was found to be the 11‐residue peptide 3.1 (KKLLKWLLKLL‐NH2), designed by Kang and co‐workers at Seoul National University (Kang et al., 2009) which exhibited an MIC of 3.13 µM against mupirocin‐resistant MRSA (Ng, Ching, et al., 2017).…”